The National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), awarded a $613,220 project grant to the University of Southern California (USC) to investigate the contribution of germline copy number variations (CNVs) to the susceptibility of aggressive prostate cancer in men of African and European ancestry. The 5-year project, starting February 1, 2025, will combine imputation and sequencing-based approaches to comprehensively assess CNVs...
The National Cancer Institute (NCI) awarded a $680,433 Project Grant under CFDA 93.394 - Cancer Detection and Diagnosis Research to The Regents of the University of California, San Francisco (UCSF) to conduct a multi-year research project titled "Multimodality Spatial Analysis in Prostate Cancer to Improve Prognostic Estimation and Cast Light into the Black Box of Pathology Artificial Intelligence Algorithms." The goal of this research is to apply cutting-edge spatial proteogenomic...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $538,553.00 to the University of Miami to conduct longitudinal imaging and liquid biopsy studies to identify markers for prostate cancer radiotherapy outcomes. The goal is to develop a multivariable model that incorporates pre-treatment and longitudinal multiparametric MRI features and circulating tumor cells to guide physicians' decisions on radiation therapy...
This Project Grant award of $704,882, provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), supports research to define the genetic basis of prostate cancer risk in African American families. The key objectives are to: Enroll additional eligible first- and second-degree affected and unaffected family members from the existing RESPOND cohort to study genetic factors contributing to familial prostate cancer risk in African American...
This Project Grant award, ID P50CA275741, was provided by the National Cancer Institute (NCI) under the Cancer Centers Support Grants program (CFDA 93.397). The $4,408,316 award to the University of California, San Francisco (UCSF) aims to address the significant public health burden of prostate cancer through translational research across four key objectives: Investigate molecular drivers of aggressive prostate cancer Develop biomarkers to guide treatment of advanced prostate cancer Target...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the Dana-Farber Cancer Institute, Inc. (DFCI) provides $627,474 to support research aimed at improving the detection, diagnosis, and understanding of prostate cancer progression. The key objectives of this 5-year project are to: 1) Identify clinically relevant epigenomic signatures in liquid biopsies that can detect the emergence of treatment-resistant neuroendocrine...
The National Cancer Institute (NCI) awarded a 5-year, $535,334 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Albert Einstein College of Medicine in Bronx, NY, effective January 1, 2025. The grant supports research to investigate the non-autonomous role of androgen signaling in prostate tumorigenesis, with a focus on understanding how stromal androgen receptor (AR) signaling in GLI1-lineage cells promotes prostate epithelial oncogenesis, tumor initiation, progression, and the...
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Louisville in the amount of $234,889 to fund research aimed at developing a novel immunotherapy regimen for prostate cancer. The research project, titled "Guadecitabine-Directed Immune Regulation in Targeting Prostate Cancer," seeks to investigate how the epigenetic modulator guadecitabine can enhance antigen presentation and increase prostate...
The National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), awarded a $632,906 Project Grant to Tulane University to study a novel role for the androgen receptor (AR) in prostate cancer progression and therapeutic resistance. The 5-year grant, which commenced on April 1, 2025, aims to elucidate how AR's RNA-binding activity promotes the expression of splicing factors, leading to efficient splicing and expression of genes critical for prostate cancer...
This Project Grant award of $683,979 from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), supports research by Weill Medical College of Cornell University to investigate the molecular mechanisms underlying prostate cancer progression and therapeutic resistance. The research aims to define how specific genetic alterations, particularly mutations in the SPOP gene, impact prostate cancer cell lineage fidelity and shape the development of...
The National Cancer Institute (NCI) awarded a $287,300 Project Grant (CFDA 93.398 Cancer Research Manpower) to the University of California, Los Angeles (UCLA) to conduct research aimed at improving prostate cancer risk stratification and clinical management. The key objectives are to investigate whether DNA damage repair gene variants, prostate cancer polygenic risk, and genetic ancestry can help predict: 1) progression from active surveillance, and 2) biochemical relapse after therapy. The research approach involves sequencing germline DNA samples from a cohort of localized prostate cancer patients and using bioinformatics to derive genomic biomarkers. Exploratory and multivariate analyses will assess associations between these genomic factors and clinical outcomes, with the goal of developing improved risk prediction models to guide prostate cancer treatment decisions. The project period runs from July 2024 through April 2027.